Telix Pharmaceuticals (TLX) Long-Term Investments (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Long-Term Investments data on file, last reported at $37.1 million in Q4 2025.

• Long-Term Investments for Q4 2025 came in at $37.1 million, up 1.12% year-over-year; the trailing twelve-month figure through Dec 2025 was $37.1 million (up 1.12% YoY), and the FY2025 annual result was $37.1 million, up 6.76% from the prior year.
• Long-Term Investments improved to $37.1 million in Q4 2025 per TLX's latest filing, from $36.7 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $37.1 million in Q4 2025 and troughed at $8.0 million in Q4 2023.
• A 3-year average of $27.3 million and a median of $36.7 million in 2024 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2024 and 2025: Long-Term Investments surged 359.61% in 2024, then gained 1.12% in 2025.
• A 3-year view of Long-Term Investments shows it stood at $8.0 million in 2023, then surged by 359.61% to $36.7 million in 2024, then advanced by 1.12% to $37.1 million in 2025.
• Business Quant data shows TLX's Long-Term Investments at $37.1 million in Q4 2025, $36.7 million in Q4 2024, and $8.0 million in Q4 2023.